Shire is to acquire rare disease company ViroPharma for $4.2 billion in a strategic move to boost its orphan drug portfolio. ViroPharma is a high growth, rare disease biopharma company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback